logo
Plus   Neg
Share
Email

Medicago, GSK Start Phase 2/3 Trials Of Adjuvanted COVID-19 Vaccine Candidate

Medicago said that it has decided to start phase 2/3 clinical trials of its plant-derived vaccine candidate for COVID-19 to evaluate its efficacy, safety, and immunogenicity. The COVID-19 vaccine candidate will contain GlaxoSmithKline plc.'s (GSK.L,GSK) pandemic adjuvant.

The move was based on the positive Phase 1 results and the approval of Canadian regulatory authorities.

Thomas Breuer, Chief Medical Officer GSK Vaccines said "...We are delighted with the very promising Phase 1 results of Medicago's COVID-19 vaccine candidate in combination with GSK's pandemic adjuvant."

The Coronavirus-Like Particle COVID-19 vaccine candidate, CoVLP is composed of recombinant spike (S) glycoprotein expressed as virus-like particles or VLPs.

According to the company, the study is a multi-portion design to confirm that the chosen formulation and dosing regimen of CoVLP (two doses of 3.75 µg CoVLP combined with GSK's pandemic adjuvant given 21 days apart) has an acceptable immunogenicity and safety profile in healthy adults 18-64 years of age and in elderly subjects aged 65 and over.

The Phase 2 trial will evaluate the safety and immunogenicity of the adjuvanted recombinant COVID-19 plant-derived vaccine candidate in subjects aged 18 and above.

Medicago noted that the phase 3 part of the study should start before the end of 2020. The phase 3 clinical trial will enroll over 30,000 volunteers worldwide.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Brazos Electric Power Cooperative Inc., the largest power generation and transmission cooperative in Texas, filed for Chapter 11 bankruptcy protection citing a huge bill from the state's grid operator following major outages recently amid the winter storm. Brazos received a $1.8 billion bill from electricity grid operator Electric Reliability Council of Texas or ERCOT. El Abuelito Cheese is recalling certain types of cheese and cheese products for fear of potential contamination with Listeria Monocytogenes, a deadly bacteria, the U.S. Food & Drug Administration said in a statement. The recall involves Queso Fresco (Fresh, soft cheese), Quesillo (Oaxaca, string cheese), and Requeson (Ricotta) products. Technology company CAE Inc. (CAE.TO, CAE) agreed Monday to acquire the military training division of aerospace and defense technology firm L3Harris Technologies Inc. (LHX) for $1.05 billion, subject to customary adjustments. The acquisition will expand CAE's position as a platform-agnostic training...
Follow RTT